Clinical Laboratory Analyzers Segment, by Type to Account Larger Share in Coagulation Market during 2022–2030

According to our latest study on “Coagulation Market Forecast to 2030 –Global Analysis – Disease Indication, Type, Offering, Technology, and End User," the market is expected to grow from US$ 6,295.28 million in 2022 and is expected to reach US$ 10,853.28 million by 2030; it is anticipated to record a CAGR of 7.0% from 2022 to 2030. The report highlights the key factors driving the coagulation market growth and prominent players with their developments in the market.

Coagulation or clotting is the process by which blood turns from a liquid into a gel and forms a blood clot. This potentially leads to hemostasis, which is the interruption of blood loss from a damaged vessel, followed by repair. Coagulation analyzer measures and evaluates the rate of clot formation or clot coagulation. It helps prevent the risk of heart attacks, embolism, and thrombosis by identifying the blood clots in the blood vessels. Obesity, heart attack, diabetes, and high blood pressure are diseases caused by lifestyle changes. Therefore, this device is a primary diagnostic tool for conditions like these. The demand for such devices in hospitals is increasing since it is a powerful automated device that serves as diagnostic tool for blood-related diseases.

Based on type, the coagulation market is bifurcated into clinical laboratory analyzers and point-of-care testing analyzers[PL1] [AD2] . Clinical laboratory analyzers are further categorized as controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others. The clinical laboratory analyzers segment held a larger share of the coagulation market in 2022. Further, the point-of-care testing analyzers segment is anticipated to register a higher CAGR from 2022 to 2030. Analyzers for point-of-care testing are used to measure the electrochemical, optical, and mechanical parameters of blood. Cutting-edge technologies, including microfluidics, fluorescent microscopy, electrochemical sensing, photoacoustic detection, and nano/micro electrochemical systems, are used to create extremely accurate, durable, and affordable point-of-care devices. Furthermore, the introduction of various point-of-care devices enabled by cutting-edge, precise, and reliable technologies helps low-volume and high-volume labs perform optical analyses of blood clotting parameters and automation. Therefore, such aforementioned factors are expected to boost the segment growth in forecast period.

Based on offering, the coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger share of the market in 2022. Further, the treatment segment is anticipated to register a higher CAGR in the coagulation market during 2022–2030. The treatment segment is further classified into anti-fibrinolytic drugs, birth control pills, desmopressin and immunosuppressive medicines, vitamin K supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapies, catheter-assisted thrombus removal, and others. Antifibrinolytics are medications that are used to stop excessive blood loss. They have been used for decades in patients undergoing certain dental or surgical procedures, and those who are susceptible to bleeding complications. Antifibrinolytics work by preventing fibrinolysis, the natural breakdown of blood clots. Anticoagulant medications, also known as blood thinners, are primarily used in the prevention and treatment of blood clots. Thrombin inhibitors are anticoagulants that inhibit the activity of thrombin by binding to it, subsequently preventing blood clot formation. In addition to preventing arterial and venous thrombosis, these medications can also be used to prevent and treat deep vein thrombosis. Thus, the segment is expected to grow due to the benefits offered by the various treatment methods for coagulation during the forecast period.

NORDIC BIOMARKER; ImproGen Diagnostik Kimya San. & Tic. Ltd.; Diagnostica Stago, Inc.; Siemens Healthcare Private Limited; Sysmex; Helena Biosciences; F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Transasia Bio-Medicals; HORIBA Medical are among the leading companies operating in the global coagulation market.    

Companies operating in the coagulation market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the coagulation market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall coagulation market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In July 2022, HORIBA Medical adds extra pre-analytical functionality to its fully automated hemostasis analyzer Yumizen G800. The new Tube Filling Level Check option for the Yumizen G800 helps to overcome a significant pre-analytical error risk factor.
• In August 2021, Siemens Healthineers Launched Sysmex CN-3000 and CN-6000 Hemostasis Systems. This fully automated CN-3000 and CN-6000 Systems bring mid- and high-volume coagulation testing to laboratories.
• In February 2021, Siemens Healthineers and Sysmex Extend Hemostasis renewed their long-standing agreement of global supply, distributorship, sales, and service for a broad portfolio of hemostasis products including a multi-year extension. As part of the agreement Siemens Healthineers agreed to distribute the new Sysmex CN Systems.
• In July 2020, Sysmex Launched  Automated Blood Coagulation Analyzers CN-6500 and CN-3500 in Japan and EMEA. These integrated analyzers incorporate features of their predecessors the CN-6000/CN-3000, such as high levels of productivity, reliability, operability, and serviceability, and come with a measuring unit using CLEIA, a measuring principle developed with HISCL.  It allow for flexible measurements in response to a broad range of test orders in the fields of thrombosis and hemostasis.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com